Creating smarter ways to fight bacteria

Leading the advancement of technologies and products
that break up biofilms and destroy bacteria.

Learn More

Kane Biotech 2021 Business Update Series

Kane Biotech Inc. introduces a 5-part 2021 business update video series, meant to offer investors and other stakeholders bite-sized explainers that discuss and layout the strategies and differentiators for each of Kane’s three strategic pillars: OTC or consumer products, animal health, and wound care.

> Watch the Video Series

Nucleus195: Diamonds in the Rough

Interview with Kane Biotech’s Chief Scientific Officer, Gordon Guay PhD, on the compelling consumer trial results of Kane’s new DermaKB™ scalp care products.

> Watch the Video
> View Trial Results

Understanding Biofilms

The study of biofilms has increased significantly in recent years due to the growing awareness of the pervasiveness and impact of biofilms on human and animal health, as well as natural and industrial systems.

Learn about Biofilms

Human Health

Biofilms are estimated to be responsible for 80% of all human bacterial infections, costing billions of dollars each year.

> Learn What We’re Doing In Wound Care & Surgical
> Learn What We’re Doing In OTC Consumer Goods

Animal Health

The companion pet market in North America has grown to an estimated $62 billion in sales per year, with the oral health care segment growing rapidly at approximately 20%.

> Learn How We’re Improving Animal Health

Industrial

The rapidly expanding industry for biomedical devices is estimated at $180 billion, yet it continues to suffer from microbial colonization. Microbial infections can develop on all medical devices and hard surfaces.

> See What’s New and Exciting

R+D

For over 10 years Kane Biotech’s R+D division has been developing new technologies and innovations leading to 52 patents and patents pending in biotechnology focusing primarily on biofilm.

> See What We’re Up To

52
1

Patents and Patents Pending